Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II).
Richard J AspinallMark HudsonStephen D RyderPaul RichardsonElizabeth FarringtonMark WrightRobert T PrzemiosloFrancisco PerezMelanie KentRoland HenrarJoe HickeyDebbie L ShawcrossPublished in: Frontline gastroenterology (2022)
Within UK clinical practice, RFX use in HE was associated with a 35% survival rate with high treatment adherence, 76% transplant-free survival rate, minimal healthcare resource and low rates of complications at 5 years post-initiation.